Volume 8, Issue 4 (2022)                   IEM 2022, 8(4): 365-378 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

pirmoradi S. Development of a New Epitope Immunogenic Structure Based on the Coronavirus Membrane Glycoprotein M Using Immunoinformatics Tools. IEM 2022; 8 (4) :365-378
URL: http://iem.modares.ac.ir/article-4-60988-en.html
PhD in Biochemistry, Department of Biochemistry, Shahid Chamran University of Ahvaz, Ahvaz, Iran , pirmoradi150@gmail.com
Abstract:   (424 Views)
Backgrounds:  Although conventional therapies have played an essential role in the treatment of many diseases, emerging diseases require new treatment methods with less complications. Therefore, it is important to develop an effective vaccine for infections caused by the coronavirus to prevent mortality and create immunity the community.
Materials & Methods: In this research bioinformatics tools were used to design a vaccine against the  M membrane protein of SARS-CoV-2.  A total of 27 epitopes confined to B cells and MHC I and II alleles were structurally constructed in M protein for immune stimulation and antibody recognition which were used in the construction of a chimeric peptide vaccine .
Results: The vaccine was predicted to be a stable, antigenic, and non-allergenic compound. TRL5/vaccine complex  analysis  and docking simulation indicated a sufficiently stable binding with appropriated receptor activation. The immune response simulation following hypothetical immunization indicated the potential of this vaccine to stimulate the production of active and memory B cells, CD8 + T and, CD4 + T cells, and effective immunological responses induced by Th2 and Th1.
Conclusion:  The analysis of in-silico processes showed that the vaccine structure induced high antigenicity and good cellular immunity in the host body and stimulates various immune receptors such as TLR5, MHC I, and MHC II. Vaccine function was also associated with an increase in IgM and IgG antibodies and a set of Th1 and Th2 cytokines. But the final confirmation of the effectiveness of the designed vaccine requires  clinical processes.
Full-Text [PDF 2768 kb]   (124 Downloads)    
Article Type: Original Research | Subject: Virology
Received: 2022/04/18 | Accepted: 2022/10/8 | Published: 2022/12/19

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.